Literature DB >> 15146430

Validation and clinical significance of the Childhood Myositis Assessment Scale for assessment of muscle function in the juvenile idiopathic inflammatory myopathies.

Adam M Huber1, Brian M Feldman, Robert M Rennebohm, Jeanne E Hicks, Carol B Lindsley, Maria D Perez, Lawrence S Zemel, Carol A Wallace, Susan H Ballinger, Murray H Passo, Ann M Reed, Ronald M Summers, Patience H White, Ildy M Katona, Frederick W Miller, Peter A Lachenbruch, Lisa G Rider.   

Abstract

OBJECTIVE: To examine the measurement characteristics of the Childhood Myositis Assessment Scale (CMAS) in children with juvenile idiopathic inflammatory myopathy (juvenile IIM), and to obtain preliminary data on the clinical significance of CMAS scores.
METHODS: One hundred eight children with juvenile IIM were evaluated on 2 occasions, 7-9 months apart, using various measures of physical function, strength, and disease activity. Interrater reliability, construct validity, and responsiveness of the CMAS were examined. The minimum clinically important difference (MID) and CMAS scores corresponding to various degrees of physical disability were estimated.
RESULTS: The intraclass correlation coefficient for 26 patients assessed by 2 examiners was 0.89, indicating very good interrater reliability. The CMAS score correlated highly with the Childhood Health Assessment Questionnaire (C-HAQ) score and with findings on manual muscle testing (MMT) (r(s) = -0.73 and 0.73, respectively) and moderately with physician-assessed global disease activity and skin activity, parent-assessed global disease severity, and muscle magnetic resonance imaging (r(s) = -0.44 to -0.61), thereby demonstrating good construct validity. The standardized response mean was 0.81 (95% confidence interval 0.53, 1.09) in patients with at least 0.8 cm improvement on a 10-cm visual analog scale for physician-assessed global disease activity, indicating strong responsiveness. In bivariate regression models predicting physician-assessed global disease activity, MMT remained significant in models containing the CMAS (P = 0.03) while the C-HAQ did not (P = 0.4). Estimates of the MID ranged from 1.5 to 3.0 points on a 0-52-point scale. CMAS scores corresponding to no, mild, mild-to-moderate, and moderate physical disability, respectively, were 48, 45, 39, and 30.
CONCLUSION: The CMAS exhibits good reliability, construct validity, and responsiveness, and is therefore a valid instrument for the assessment of physical function, muscle strength, and endurance in children with juvenile IIM. Preliminary data on MID and corresponding levels of disability should aid in the clinical interpretation of CMAS scores when assessing patients with juvenile IIM.

Entities:  

Mesh:

Year:  2004        PMID: 15146430     DOI: 10.1002/art.20179

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  55 in total

Review 1.  Update on the assessment of children with juvenile idiopathic inflammatory myopathy.

Authors:  Adam M Huber
Journal:  Curr Rheumatol Rep       Date:  2010-06       Impact factor: 4.592

Review 2.  Recent advances in juvenile dermatomyositis.

Authors:  Ann M Reed; Thomas Mason
Journal:  Curr Rheumatol Rep       Date:  2005-04       Impact factor: 4.592

3.  An interferon signature in the peripheral blood of dermatomyositis patients is associated with disease activity.

Authors:  Emily C Baechler; Jason W Bauer; Catherine A Slattery; Ward A Ortmann; Karl J Espe; Jill Novitzke; Steven R Ytterberg; Peter K Gregersen; Timothy W Behrens; Ann M Reed
Journal:  Mol Med       Date:  2007 Jan-Feb       Impact factor: 6.354

4.  Alternative scoring of the Cutaneous Assessment Tool in juvenile dermatomyositis: results using abbreviated formats.

Authors:  Adam M Huber; Peter A Lachenbruch; Elizabeth M Dugan; Frederick W Miller; Lisa G Rider
Journal:  Arthritis Rheum       Date:  2008-03-15

Review 5.  Juvenile dermatomyositis: advances in clinical presentation, myositis-specific antibodies and treatment.

Authors:  Jian-Qiang Wu; Mei-Ping Lu; Ann M Reed
Journal:  World J Pediatr       Date:  2019-09-26       Impact factor: 2.764

6.  Favorable outcome of juvenile dermatomyositis treated without systemic corticosteroids.

Authors:  Deborah M Levy; C April Bingham; Philip J Kahn; Andrew H Eichenfield; Lisa F Imundo
Journal:  J Pediatr       Date:  2009-10-28       Impact factor: 4.406

Review 7.  Long-term outcomes in juvenile dermatomyositis: how did we get here and where are we going?

Authors:  Adam Huber; Brian M Feldman
Journal:  Curr Rheumatol Rep       Date:  2005-12       Impact factor: 4.592

8.  Juvenile dermatomyositis: new insights and new treatment strategies.

Authors:  Neil Martin; Charles K Li; Lucy R Wedderburn
Journal:  Ther Adv Musculoskelet Dis       Date:  2012-02       Impact factor: 5.346

9.  Anti-CD52 antibody-mediated immune ablation with autologous immune recovery for the treatment of refractory juvenile polymyositis.

Authors:  Andreas Reiff; Bracha Shaham; Kenneth I Weinberg; Gay M Crooks; Robertson Parkman
Journal:  J Clin Immunol       Date:  2011-05-04       Impact factor: 8.317

Review 10.  Juvenile dermatomyositis.

Authors:  Michelle Batthish; Brian M Feldman
Journal:  Curr Rheumatol Rep       Date:  2011-06       Impact factor: 4.592

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.